MTOR and primary effusion lymphoma: In fact, cells from primary effusion lymphoma (PEL), a subtype of B cell non-Hodgkin's lymphoma with a median patient survival duration of 6 months, provide support for this hypothesis [23]. In vitro, these cells exhibit an increased dependence on aerobic glycolysis through the PI3 K/AKT/mTOR pathways that control glycolysis via GLUT1 [24].